WORKSHOP MOLECULAR PROGNOSTIC MARKERS OCTOBER 2008

The identification of molecular genetic changes such as gene mutations or deregulated gene expression has greatly advanced our understanding of the pathogenesis of acute myeloid leukemia (AML). These markers now allow us to dissect the enormous heterogeneity that is seen within cytogenetically defined subgroups of AML. In part, these markers have been shown to be of great prognostic implication. Furthermore, these genetic changes are providing targets for molecular therapeutic approaches. In this workshop, leading experts in the field will review current knowledge and present the latest developments on the pathogenesis and clinical impact of biomarkers as well as data on new molecular alterations derived from innovative genomics technologies.

If you would be interested in taking part as a participant, please visit www.esh.org/agenda08.htm to register on line and to book your hotelaccommodation. You are also welcome to contact EHA: education@ehaweb.org or ESH: marie-france.simon@univ-paris-diderot.fr for any supplementary information.

GENERAL DESCRIPTION WORKSHOPS

ESH-EHA scientific workshops are organized under the auspices of the newly founded ESH-EHA Joint Executive Committee. They state-of-the-art science and are intended to promote informal interaction and discussion between scientists and clinicians working in the field. Two or three times a year different workshops are organized in Mandelieu (near Cannes), France. Participants are encouraged to contribute to the workshop by submitting an abstract which may be selected for either a poster or a short oral presentation.

Preliminary program

Friday October 3, 2008

13:00 – 14:00 Welcome Lunch Buffet

14:00 – 14:15 Welcome: Purpose of Meeting (B. Löwenberg & H. Döhner)

14:15 – 16:30SESSION I - GENE MUTATIONS (I)

Chair:H. Dombret

14:15 – 14:35 NPM1: Biology and prognostic significance - B. Falini

14:35 – 14:50 NPM1: Prognostic significance - K. Döhner

14:50 – 15:05 NPM1: Therapeutic targeting- R. Schlenk

15:05 – 15:20 FLT3: Prognostic significance - R. Gale

15:20 – 15:35 FLT3: Prognostic significance : allelic ratio - C. Thiede

15:35 – 15:50 FLT3: Therapeutic targeting- D. Small

15:50 – 16:30 Round table

16:30 – 17:00 Coffee break

17:00 – 19:15SESSION II - GENE MUTATIONS (II)

Chair:C. Bloomfield

17:00 – 17:15 CEBPA: Biology and prognostic significance - H. Dombret

17:15 – 17:30 CEBPA: Familial AML - T. Pabst

17:30 – 17:45 KIT: Prognostic significance - P. Paschka

17:45 – 18:00 WT1: Prognostic significance - J. Fitzgibbon

18:00 – 18:15 MLL: Biology and prognostic significance - S. Whitman

18:15 – 18:30 AML1: Biology and relation to cytogenetics - S. Schnittger

18:30 – 19:15 Round table

Saturday October 4, 2008

08:30 – 10:00 SESSION III - PROGNOSTIC IMPACT OF CYTOGENETICS:

CYTOGENETIC MARKERS REVISITED

Chair: J. Sierra

08:30 – 08:50 Cytogenetic markers - C. Bloomfield

08:50 – 09:10 Cytogenetic markers - B. Löwenberg

09:10 – 09:30 Cytogenetic markers - D. Grimwade

09:30 – 10:00 Round table

10:00 – 10:30 Coffee break

10:30 – 12:15 SESSION IV - GENE EXPRESSION

Chair: D. Grimwade

10:30 – 10:45 BAALC: Biology and prognostic significance - C. Baldus

10:45 – 11:00 EVI1: Biology and prognostic significance - R. Delwel

11:00 – 11:15 ERG: Biology and prognostic significance - G. Marcucci

11:15 – 11:30 MN1: Biology and prognostic significance - A. Ganser

11:30 – 12:15 Round table

12:15 – 14:00 Lunch

14:00 – 16:15 SESSION V – GENOME WIDE TECHNOLOGIES (I)

Chair:B. Ebert

14:00 – 14:20 SNP in Pediatric AML - J. Downing

14:20 – 14:40 SNP in Adult AML - B. Young

14:40 – 14:55 Gene expression profiling - P. Valk

14:55 – 15:10 Gene expression profiling - L. Bullinger

15:10 – 15:25 Gene expression profiling - T. Haferlach

15:25 – 15:40 Gene expression profiling - M. Radmacher

15:40 – 16:15 Round table

16:15 – 16:45 Coffee break

16:45 – 18:45SESSION VI - GENOME WIDE TECHNOLOGIES (II)

Chair: J. Downing

16:45 – 17:05 MicroRNA profiling - G. Marcucci

17:05 – 17:25 MicroRNA profiling - M. Jongen

17:25 – 17:45 Functional genomics screen - B. Ebert

17:45 – 18:05 Epigenetic profiling - C. Plass

18:05 – 18:45 Round table

SUNDAY October 5, 2008

08:30 – 11:15 SESSION VII - TOWARDS AN INTEGRATED PROGNOSTIC

ALGORITHM

Chairs: E. Estey & A. Burnett

08:30 – 08:45 Considerations about a composite prognostic score TBA

08:45 – 09:00 Considerations about a composite prognostic score - C. Bloomfield

09:00 – 09:15 Considerations about a composite prognostic score - A. Burnett

09:15 – 09:30 Considerations about a composite prognostic score - H. Döhner

09:30 – 09:45 Considerations about a composite prognostic score - H. Dombret

09:45 – 10:00 Considerations about a composite prognostic score - E. Estey

10:00 – 10:30 Coffee break

10:30 – 10:45 Considerations about a composite prognostic score - B. Löwenberg

10:45 – 11:00 Considerations about a composite prognostic score - J. Sierra

11:00 – 11:15 Considerations about a composite prognostic score - M. Tallman

11:15 – 12:00 SESSION VIII – OPEN FORUM

Chairs: H. Döhner & B. Löwenberg

Final Discussion, Conclusions, Recommendations

12:00 – 13:30 Farewell lunch